Mark and Amy dig into a new JAMA Network Open study that used AI to sort nearly 150,000 Reddit posts about unapproved retatrutide. Users report hunger, fatigue and a racing heart; the TRIUMPH trials found mostly stomach effects. They walk through where the two pictures match, why they differ, how glucagon sets retatrutide apart from tirzepatide, and HHS's new peptide access plan.
In this episode
- 00:00 Theme, cold open and intro
- 00:50 Amy's forum night and Mark's Lancet weekend
- 01:10 What 7,800 Reddit users reported
- 02:19 What the TRIUMPH-2 trial actually found
- 03:23 Why the two pictures differ: the limits
- 04:22 Where glucagon and the GLP-1 drugs overlap and split
- 05:00 Quick hit: HHS peptide access plan and BPC-157
- 05:30 Safety fine print and the bottom line
- 05:55 Wrap-up and Amino Club code
Peptides covered
Free tools
- Free reconstitution and dosing calculator: mypeps.info/calculator
Sources
- Penn engineers use AI, Reddit to identify potential side effects of unapproved new GLP-1 (on the JAMA Network Open study "Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide," published Oct 14, 2026) — University of Pennsylvania via EurekAlert!, Oct 15, 2026. https://www.eurekalert.org/news-releases/1147934
- Sehgal NKR, Ungar L, Tronieri JS, Rader B, Guntuku SC. Self-Reported Side Effects Among Reddit Users Taking Nonapproved Retatrutide — medRxiv, Aug 18, 2026 (preprint version of the study above, not peer reviewed; analysis of community discussion). https://www.medrxiv.org/content/10.64898/2026.05.28.26352819v2.full.pdf
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial — The Lancet, Oct 10, 2026 (online Sep 29, 2026). https://pubmed.ncbi.nlm.nih.gov/42810372/
- Retatrutide cuts weight up to 18.8% in adults with T2D, obesity — Pharmacy Times, Sep 30, 2026. https://www.pharmacytimes.com/view/retatrutide-cuts-weight-up-to-18-8-in-adults-with-t2d-obesity
- Was dysesthesia reported as an adverse event in the retatrutide TRIUMPH trials? — Lilly Medical, reviewed Aug 18, 2026. https://medical.lilly.com/us/products/answers/was-dysesthesia-reported-as-an-adverse-event-in-the-retatrutide-triumph-trials-in-patients-with-overweight-or-obesity-387925
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine, 2023 (background). https://pubmed.ncbi.nlm.nih.gov/37366315/
- Ard JD, Almandoz JP. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and MASH — Obesity Reviews, Oct 11, 2026. https://pubmed.ncbi.nlm.nih.gov/42860310/
- Perrone M. Trump administration advances plan for peptide drugs favored by RFK Jr. — Associated Press via News4JAX, Oct 15, 2026. https://www.news4jax.com/business/2026/10/15/trump-administration-advances-plan-for-peptide-drugs-favored-by-rfk-jr/
Where we buy
Amino Club publishes an independent lab report (COA) for every lot; see them on our lab reports page. Their products are sold for research use only, not for human use: aminoclub.com, 40% off with code MYPEPSINFO. This is an affiliate link, so we may earn a commission.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs. Mark and Amy are AI-generated voices; every episode is reviewed by our editor, Ryan E., MS.